Spironolactone and acute mountain sickness

Thirteen adults trekking in Nepal in 1974 to altitudes between 4,300 m and 5,500 m remained free from acute mountain sickness while taking spironolactone as a prophylactic measure. Two years previously five of these adults trekking at similar altitudes, but without treatment, had suffered from acute...

Full description

Saved in:
Bibliographic Details
Published inMedical journal of Australia Vol. 2; no. 5; p. 168
Main Authors Currie, T T, Carter, P H, Champion, W L, Fong, G, Francis, J K, McDonald, I H, Newing, R K, Nunn, I N, Sisson, R N, Sussex, M, Zacharin, R F
Format Journal Article
LanguageEnglish
Published Australia 31.07.1976
Subjects
Acute Disease
Adult
Altitude Sickness - drug therapy
Altitude Sickness - prevention & control
Aspirin - therapeutic use
Female
Furosemide - therapeutic use
Humans
Hypoxia - prevention & control
Male
Middle Aged
Mountaineering
Nepal
Spironolactone - therapeutic use
Sports Medicine
Online AccessGet more information

Cover

More Information
Summary:Thirteen adults trekking in Nepal in 1974 to altitudes between 4,300 m and 5,500 m remained free from acute mountain sickness while taking spironolactone as a prophylactic measure. Two years previously five of these adults trekking at similar altitudes, but without treatment, had suffered from acute mountain sickness. The regime used was spironolactone in a dosage of 25 mg three times a day for two days preceding and during the periods spent at altitudes above 3,000 m.
ISSN:0025-729X
DOI:10.5694/j.1326-5377.1976.tb134450.x